



Resource impact template

Resource impact

Published: 8 May 2025

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for untreated EGFR mutation-positive advanced non-small-cell lung cancer:

- [Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer](#) (2026) NICE technology appraisal guidance 1122
- [Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer](#) (2025) NICE technology appraisal guidance 1060